FDA Perspectives: Designation of Regulatory Starting Materials in the Manufacturing of Drug Substances: Impact on ANDA Review Time - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

FDA Perspectives: Designation of Regulatory Starting Materials in the Manufacturing of Drug Substances: Impact on ANDA Review Time
The author describes how providing appropriate information about the API in the Common Technical Document can aid FDA's review of an abbreviated new drug application.


Pharmaceutical Technology
Volume 36, Issue 1, pp. 63-66

Chemical synthesis


Figure 1: Case I—unacceptable.
The starting material should be removed from the finished product by multiple synthetic steps with intermediates isolated and in-process controls specified. Salt interconversions, saponifications, esterifications, recrystallization steps, resolution of racemates, and in-situ reactions with no intermediate isolated do not count as synthetic steps. In Case I (Figure 1), the starting material selection is considered inappropriate because the synthesis is only one step removed from the finished product (salt interconversion is not a valid synthetic step). Furthermore, all of the key structural elements found in the API are already included in the proposed starting material.


Figure 2: Case II—unacceptable.
For chiral molecules, how each stereocenter is introduced should be discussed in detail; proof of characterization using chiral methodologies should be provided; and appropriate in-process controls should be highlighted. In Case II (Figure 2), the starting material is inappropriate because all chiral centers A, B, and C are set in the proposed starting material with no indication of how they were put in place or resolved.


Figure 3: Case III—unacceptable.
In Case III (Figure 3), the racemate is purchased, resolved, and purified. There are no reaction steps or isolated intermediates, and therefore, the racemate is not an acceptable starting material.

This also applies even in cases where the racemate is a drug substance in and of itself. For example, consider the case of the API dexmethylphenidate. The racemate, methylphenidate, which is also an API, cannot be declared a starting material, as there is only a resolution step involved in transforming it to dexmethylphenidate.


Figure 4: Case IV—unacceptable.
Molecules that contain potential genotoxic (4, 5) structural elements in intermediates anywhere along the synthetic route require extra care in managing impurity profiles and the corresponding risk associated with them. Designating a starting material too late in a synthetic route with no information regarding impurity carryover and purification methods is not acceptable. In Case IV (Figure 4), the DMF holder proposes the bis-anilino moiety as the starting material. A cyclization step and further purification leads to the finished product. Aryl aniline functionalities are known carcinogens and are quite frequently derived from aryl nitro groups, a well-known genotoxic functional group (4). From a risk-based point of view, controls of the impurities at the nitration step are critical in this manufacturing scheme. The proposed bis-anilino starting material gives no indication on how the nitration step was controlled or how subsequent impurities were removed. Furthermore, the proposed starting material is only one step from the finished product with no intermediate isolated in between.

If a molecule is "well defined" in the literature, then the literature should be cited along with appropriate detailed comparative structural analysis from the DMF holder against the literature values (e.g., published papers and patents). It is recommended that data from multiple lots using the commercial process to demonstrate sameness be provided for review.

Commercially available starting materials need not be justified. In this context and per the draft ICH Q11, commercially available means "a chemical that is sold as a commodity in a pre-existing, non-pharmaceutical market" (2). In contrast, chemicals for which a contract manufacturer custom synthesizes a predefined amount of material specifically for the DMF holder are not considered "commercially available." Primary DMF holders submitting syntheses defining non-commercially available starting materials will be asked a number of questions including the following:


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here